US OptionsDetailed Quotes
XBI241018P97000
- 0.09
- -0.12-57.14%
15min DelayTrading Oct 16 12:37 ET
0.19High0.09Low
0.18Open0.21Pre Close78 Volume4.65K Open Interest97.00Strike Price1.32KTurnover31.44%IV3.38%PremiumOct 18, 2024Expiry Date0.00Intrinsic Value100Multiplier2DDays to Expiry0.09Extrinsic Value100Contract SizeAmericanOptions Type-0.0854Delta0.0651Gamma1055.79Leverage Ratio-0.0741Theta-0.0005Rho-90.21Eff Leverage0.0119Vega
SPDR S&P Biotech ETF Stock Discussion
With the Fed's September meeting likely to deliver a rate decrease, the question arises: how should investors allocate assets during an interest rate cut cycle? Let's delve into the tactics and consid...
The upcoming interest rate cuts are poised to benefit the biotech stock industry, setting the stage for strong performance in the coming quarters.
Reasons:
Cheaper Funding: Lower interest rates make it easier for biotech companies to access capital for research and development, accelerating their progress and growth potential.
Attractive Valuations: Biotech stocks are currently trading at attractive levels, offering investors an opportunity to capitalize on the sector's long-term pot...
» Is this a smid-cap biopharma buying opportunity? 🤔
Stock market sell-off, e.g., $NASDAQ, started late last week on weak jobs data
XBI/smid-cap biopharma were part of sell-off
But..
» Is this sell-off justified for smid-cap biopharma?
» Is this a buying opportunity for smid-cap biopharma?
💡 Lower economic/jobs data = more likely entering lowering interest rate cycle for Fed Reserve
Usually go...
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF XBI 0.05% drop nearly 50%.
The other most-watched exchange-traded fund that tracks the biotech secto...
It does not follow the XBI and Russell 2000 up trend for this period of time. Meaning market drops, it drops. Market ups, it still drop. Gonna cut off from my side
$Merck & Co (MRK.US)$ already has an active partnership with $Janux Therapeutics (JANX.US)$ for two TRACtr targets, and CEO Davis has evinced a preference for acquisition of $SPDR S&P Biotech ETF (XBI.US)$ in which $Merck & Co (MRK.US)$ already has a seat at the table.
$Merck & Co (MRK.US)$ acquisition of $HARP earlier this year (for a song) shows their interest in the T Cell engag...
$Bristol-Myers Squibb (BMY.US)$ is a global biopharmaceutical company known for its innovative treatments in oncology, immunology, and cardiovascular diseases. Over the past year, BMY has faced some challenges, with its stock price nearing its 52-week low. As of June 20, 2024, the stock is trading at $40.795, which is close to its 52-week low of around $40.00.
$Bristol-Myers Squibb (BMY.US)$
Despite recent performance s...
Interesting list of name for the incoming CPI..
$Novavax (NVAX.US)$ $SPDR S&P Biotech ETF (XBI.US)$ $S&P 500 Index (.SPX.US)$
2 biggest deals this yr:
$Vertex Pharmaceuticals (VRTX.US)$ paid $4.9 bil for $Alpine Immune (ALPN.US)$
$Gilead Sciences (GILD.US)$ paid $4.3 bil for $CBAY
Bolt-on deals likely to continue to be the dominant story in 2024, which means we could also see more of this trend...
Last yr 84% of M&A deal dollars were for Biotechs w/ Phase 3 & Marketed assets,
In the first four months of 2024 56% of M&A deal dollar went towards P...
No comment yet